CBOE vs CME: Contrasting Paths for Two Exchange Operators
Key Takeaways
- Both CBOE and CME are exchange operators that posted record financial results recently, but they derive growth from different product mixes and customer bases.
- CBOE is skewing toward options, index products, and data under a new CEO, while divesting smaller international businesses to sharpen focus.
- CME dominates futures and clearing, and is investing in 24/7 crypto trading, event contracts, and a new securities clearinghouse as growth drivers.
- Analyst sentiment has diverged somewhat: CBOE received a recent upgrade, while CME carries a more mixed rating profile despite record volumes.
- Relative performance favors different profiles — CBOE leans on higher-margin index and data revenue, while CME offers greater scale and diversification across interest rates, energy, metals, and crypto.
- For ongoing coverage, explore CBOE Major News and CBOE Today's Price Move, plus CME Major News and CME Today's Price Move.
- To see how AI approaches this and other comparisons in real time, browse the Trending AI Robots.
Why These Exchange Names Stand Out
Exchange operators tend to generate steady cash flows from trading activity no matter which way markets move. CBOE and CME rank among the most visible players here, yet they focus on different parts of the derivatives and securities landscape. This comparison matters for investors weighing how product focus, innovation, and performance stack up between a broad futures and clearing business and an options-and-index specialist. I also checked this using Tickeron’s AI Screener to see how the two compare within the broader industry group.
CBOE's Strategic Shift
Cboe Global Markets, Inc. (CBOE) runs options, futures, and securities exchanges and is particularly known for its index options such as S&P 500 Index (SPX) options and VIX volatility products. The firm recently posted record quarterly revenue, supported by double-digit growth in options and solid results in derivatives and data. Adjusted earnings per share increased notably year over year thanks to higher volumes and better operating leverage.
Under new leadership the company is streamlining. It plans to exit smaller operations in Australia and Canada, scale back parts of its European derivatives platform, and stop corporate listings work. These steps aim to concentrate resources on core index and options offerings. Barclays recently upgraded CBOE to Overweight, pointing to healthy index-options growth and the clearer strategy. Key risks remain around concentration in flagship products and ongoing fee competition.
CME's Expansion Focus
CME Group Inc. (CME) operates the largest futures exchange, covering interest rates, equities, energy, agriculture, metals, and foreign exchange. It reported its fourth straight year of record annual revenue and adjusted earnings, with quarterly revenue rising on higher clearing and transaction fees. Average daily volume hit new highs, helped by equities, metals, and cryptocurrency products.
Growth initiatives rather than cutbacks are driving the narrative. Management is pushing 24/7 crypto trading, a new securities clearinghouse, and event contracts that have already seen early volume. Crypto-related daily volumes rose sharply and market data revenue reached a record. The firm noted higher 2026 expenses tied to these moves, which analysts balance against its otherwise stable margins. Ratings remain mixed, with one upgrade to Buy offset by neutral stances elsewhere.
Side-by-Side View
The main difference lies in business mix. CME is the larger and more diversified player, with revenue spread across a wide futures and clearing operation and a market capitalization above $100 billion. CBOE is smaller and more focused, with heavy reliance on proprietary index options and data that deliver strong margins but bring product-specific exposure.
Growth approaches also diverge. CBOE is tightening its scope by extending near-24-hour index-options trading and emphasizing high-margin data and index revenue while shedding smaller units. CME is broadening through crypto, event contracts, and clearing infrastructure. Risks follow the strategies: CBOE faces concentration and execution challenges from its restructuring, while CME contends with expense growth and integration of new initiatives. Both delivered record results, though CBOE has shown stronger near-term analyst momentum while CME benefits from scale and steadier performance.
AI-Based Assessment
Looking at trend consistency, catalysts, and positioning, the probabilistic view points to a modest edge for CBOE in the near term. Record earnings, the recent upgrade, and a strategy centered on higher-margin index and options products create a clearer set of near-term drivers compared with CME's longer-term investment programs. That said, CME brings greater stability, diversification, and scale that may suit more risk-averse or extended time horizons. The edge can shift with new volume and earnings data.
AI Tools in Practice
In my own work I have found Tickeron’s AI Trading Bots helpful for monitoring names like these across different market conditions. The platform hosts a range of automated strategies with varying styles, timeframes, and performance histories, allowing users to review which models align best with current trends. Readers can explore the available bots and their statistics directly on the site.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CME in upward trend: 10-day moving average moved above 50-day moving average on October 14, 2026
The 10-day moving average for CME crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 08, 2026. You may want to consider a long position or call options on CME as a result. In 61 of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 58%.
The Moving Average Convergence Divergence (MACD) for CME just turned positive on October 08, 2026. Looking at past instances where CME's MACD turned positive, the stock continued to rise in 24 of 47 cases over the following month. The odds of a continued upward trend are 51%.
CME moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where CME advanced for three days, in 170 of 341 cases, the price rose further within the following month. The odds of a continued upward trend are 50%.
The Aroon Indicator entered an Uptrend today. In 139 of 267 cases where CME Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 41%.
CME broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 18 (best 1 - 100 worst), indicating outstanding price growth. CME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 34 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 75, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 42 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.145) is normal, around the industry mean (4.090). P/E Ratio (25.798) is within average values for comparable stocks, (18.317). CME's Projected Growth (PEG Ratio) (4.578) is very high in comparison to the industry average of (1.780). Dividend Yield (0.017) settles around the average of (0.018) among similar stocks. CME's P/S Ratio (14.535) is slightly higher than the industry average of (7.166).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an operator of securities and commodity exchanges
Industry FinancialPublishingServices
Advertisement